Using BPC-157 or Other Peptides? What Patients With Headache or Cognitive Concerns Should Know

An evidence-based, nonjudgmental guide for people experiencing migraine changes, headache, brain fog, or memory concerns while using peptides

Peptides such as BPC-157 are increasingly discussed in longevity clinics, wellness practices, podcasts, and online communities. People may try them for pain, injury recovery, healing, digestive concerns, or health optimization.

Some later wonder whether a new headache, a change in migraine, brain fog, poor sleep, dizziness, or a memory concern could be related. Others are focused on protecting cognitive health because of age, family history, or concern about Alzheimer’s disease or another dementia.

These questions fall directly within the two main areas of my neurology practice: headache and migraine care, and memory and cognitive health. They also often overlap with lifestyle, weight and metabolic health, menopause, hormone therapy, and GLP-1 treatment.

At Cardiel Precision Brain Health, you can discuss peptide use openly. I will not automatically blame the peptide, or ignore it. The goal is to understand the full picture and determine what deserves further evaluation.

The quick take

• BPC-157 is not FDA-approved for any medical condition.

• It has not been proven to treat migraine, improve memory, lower Alzheimer’s risk, or prevent another dementia.

• A new preprint found encouraging patient reports, but it cannot establish that BPC-157 caused the improvements.

• Headache, insomnia, anxiety, and mood changes appeared among grouped signals in the records, but the study cannot show whether BPC-157 caused them.

• If you use BPC-157 or another peptide, sharing the details with your neurologist can improve diagnostic accuracy and safety.

What did the new BPC-157 study find?

A September 2026 preprint identified 1,039 patients with documented BPC-157 use in a large U.S. health-record network.

Of the 354 patients whose notes included a clear response, 279 reported improvement, 58 reported no change, and 17 reported worsening. That is where the widely shared 78.8% improvement figure comes from.

However, 685 of the 1,039 users, almost two-thirds, had no clear response recorded. The study also had no comparison group, standardized product or dose, or objective system for measuring improvement. About half of the patients were using at least one other treatment, making it difficult to know what produced any change.

The findings are worth studying further. They do not demonstrate a 79% success rate.

Why peptide use matters in headache and migraine care

When headaches become more frequent, more severe, or different from your usual pattern, the timing of every new exposure matters. That includes prescriptions, over-the-counter medications, supplements, hormones, GLP-1 medications, and peptides.

A peptide may turn out to be unrelated. It should still be included when evaluating migraine changes, medication effects, sleep disruption, or a secondary cause of headache.

Why it matters in memory and cognitive care

People concerned about Alzheimer’s disease or another dementia are often highly motivated to protect their health. They may improve nutrition and exercise, address weight or insulin resistance, consider hormone therapy, use supplements, and explore emerging treatments, sometimes all at once.

That motivation is valuable, but it can become difficult to tell which intervention is helping and which claims are ahead of the science. Brain fog, word-finding difficulty, attention problems, and memory changes deserve an appropriate evaluation rather than being automatically blamed on aging, menopause, stress, or a peptide.

There is currently no good clinical evidence that BPC-157 improves memory, changes Alzheimer’s biomarkers, or prevents Alzheimer’s disease or another dementia.

My training in lifestyle medicine, obesity medicine, and menopause care helps me evaluate sleep, metabolic health, weight treatment, hormonal factors, and lifestyle while keeping the neurologic concern at the center.

Can BPC-157 cause headache, brain fog, or sleep changes?

Current research cannot answer that reliably.

In the new study, neurologic or psychiatric events were documented infrequently as a group. Examples included headache, insomnia, anxiety, and mood change. But these findings came from routine medical notes—not from a study designed to track side effects carefully.

The records cannot prove that BPC-157 caused a symptom or that the product is safe. If a symptom began or changed after starting a peptide, the timing is still important. A neurologist can consider migraine, sleep, medication or supplement effects, hormonal or metabolic changes, and other neurologic explanations.

When should a peptide user see a neurologist?

Consider an evaluation if you experience:

• A new headache or meaningful change in your usual headache pattern

• More frequent or severe migraine attacks

• Persistent brain fog, forgetfulness, reduced concentration, or word-finding difficulty

• Concern about cognitive decline because of symptoms or family history of Alzheimer’s disease or another dementia

• Dizziness, imbalance, unusual tingling, numbness, weakness, or tremor

• Sleep disruption accompanied by worsening headaches or cognitive symptoms

• Neurologic symptoms after adding or combining peptides, hormones, supplements, or metabolic medications

• Uncertainty about how an emerging therapy fits with your migraine or brain-health plan

You do not need to determine whether the peptide caused the problem before seeking care. That is part of the evaluation.

When not to wait for an appointment

Call 911 for a sudden severe or “worst” headache, new one-sided weakness or numbness, facial drooping, difficulty speaking, a seizure, severe confusion, loss of vision, fainting, or difficulty breathing. These symptoms require urgent assessment regardless of peptide use.

What to bring to your visit

Peptide products may not appear in a standard pharmacy record. Bring:

• The product name, reason for using it, and where it came from

• A photograph of the label and packaging

• The manufacturer or pharmacy and lot number, if available

• The dose, route, schedule, and dates of use

• A timeline showing when symptoms began or changed

• A complete list of medications, supplements, hormones, GLP-1 medications, and other peptides

For headache concerns, track monthly headache days, migraine days, rescue-medication use, and changes in function.

My approach to patients using peptides

My current position is that the evidence does not support routinely recommending BPC-157. That does not mean I am unaware of the research or unwilling to care for people who use it.

An individualized neurologic evaluation can help reconstruct the timeline, look for urgent or more common explanations, review overlapping treatments, and decide whether headache tracking, cognitive assessment, laboratory testing, or imaging is appropriate.

Evidence-based care should make room for an honest conversation. You should be able to tell your neurologist what you are taking without expecting ridicule—and receive a clear explanation of what is known, what remains uncertain, and what should happen next.

The bottom line

The new BPC-157 report contains an encouraging signal, but it does not prove 79% efficacy, establish long-term safety, or support BPC-157 for migraine or cognitive decline.

If you are using a peptide and have a neurologic concern, do not hide the peptide—and do not assume it explains everything. A careful evaluation should consider both the emerging therapy and the full neurologic picture.

Using a peptide and concerned about headache or cognition?

Cardiel Precision Brain Health offers extended, individualized evaluations in two principal areas:

• Headache and migraine care

• Memory and cognitive health, including concerns about Alzheimer’s disease and other dementias

When relevant, the evaluation can also incorporate sleep, lifestyle, weight and metabolic health, menopause, hormone therapy, and GLP-1 treatment.

When requesting a consultation, include the peptide or emerging therapy you are using and whether your concern involves headache, migraine, memory, cognition, or dementia risk.

Sources and further reading

• Venkatakrishnan and colleagues: BPC-157 utilization and patient-reported outcomes preprint — posted September 7, 2026; not peer-reviewed

• FDA scientific review of BPC-157-related bulk drug substances

• FDA information about bulk substances used in compounding under section 503A

• Systematic review of BPC-157 in orthopaedic sports medicine

• CDC information about stroke symptoms and when to call 911

About Myrna Cardiel, MD

Myrna Cardiel, MD, is a board-certified neurologist and the founder of Cardiel Precision Brain Health. With more than 20 years of clinical experience, her two principal areas of focus are headache and migraine care, and memory and cognitive health, including concerns about Alzheimer’s disease and other dementias. She is also board-certified in lifestyle medicine, a Diplomate of the American Board of Obesity Medicine, and a Menopause Society Certified Practitioner. Her approach places metabolic health, weight treatment, hormonal health, and lifestyle factors into an individualized neurologic context.

This post is for educational purposes and is not individualized medical advice. Do not start, stop, or change a treatment based solely on this post. Discuss treatment decisions and new or worsening symptoms with a qualified clinician